Cardiovascular disease
Conditions
Interventions
control group:took a placebo daily (1 tablets per dose, twice daily)
Betaine group:took a Betaine daily (1 tablets per dose, twice daily)
Sponsors
The Seventh Affiliated Hospital, Sun Yat-sen University (Shenzhen)
Eligibility
Sex/Gender
All
Age
40 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age 40-65 years; 2. No gender restriction; 3. Average weekly drinking frequency greater than 1 time in the past six months, with each occasion exceeding 100ml of distilled spirits or 500ml of beer; 4. SAH level >50nmol/L upon initial examination; 5. Possess basic reading ability, own a smartphone, and be able to use social software such as WeChat; 6. Agree to participate, can actively cooperate with the study and complete follow-up visits, and provide a signed informed consent form.
Exclusion criteria
Exclusion criteria: 1. Subjects with a history of or currently diagnosed with any tumor; 2. Subjects who are currently pregnant, have been pregnant or lactating within the past two years, or plan to become pregnant within the next year; 3. Subjects diagnosed with AIDS; 4. Subjects with unstable angina, those who have experienced acute myocardial infarction within the past six months, or those who have undergone recent surgical intervention; 5. Subjects unable to undergo and complete the intervention treatment due to mental disorders, physical disabilities, other medical conditions, or constitutional issues; 6. Subjects concurrently, recently, or planning to participate in other clinical trials, weight-loss programs, or other intervention studies; 7. Subjects currently using weight-loss medications; 8. Subjects taking any vitamins or medications that may affect homocysteine levels, or currently following a clinically prescribed diet; 9. Subjects with severe cardiovascular disease, diabetes, liver failure, or any life-threatening disease with a prognosis of less than five years; 10. Subjects with any other condition that, in the investigator's judgment, would hinder participation or may affect protocol adherence.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Brachial artery endothelial dilation function; | — |
Secondary
| Measure | Time frame |
|---|---|
| weight;height;Waist circumference;hip circumference;body fat percentage;Blood pressure;Oxidative stress level;SAM level;SAH level;tHCY level;Routine blood indexes;Inflammatory factors; | — |
Countries
China
Contacts
Public ContactXiao Yunjun
The Seventh Affiliated Hospital, Sun Yat-sen University(Shenzhen)
Outcome results
None listed